QPS recently established its second preclinical research facility in Taipei, Taiwan, according to a press release.
"Preclinical research across various species is a crucial step in the drug development process. Assessing toxicology and safety in these early stages of the research process helps to ensure that new drugs are safe enough to be allowed to progress to First in Human (FIH) clinical research trials," deputy general manager and head of the Center of Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan, Dr. Chen said.
Spanning 2,793 square feet, the new facility, scheduled to begin operations in December 2022, is intended to expand research surrounding toxicology studies and pharmacology studies.
It will also make way for flexible scheduling and additional space to expand toxicology operations and create a new pharmacology unit.
The facility, fully accredited animal centers and a pharmacology unit, will initially target multi-species capabilities in wound healing models, and services for irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH) and atopic dermatitis.
Experts based at the facility will begin conducting studies on various species in 2023.
QPS welcomed Dr. Mei-Ling Hou, Ph.D. to lead the new pharmacology department.
“Aligning with the biotech and pharmaceutical industry from preclinical through clinical studies, this new center of excellence will ensure that QPS has the skills, capabilities and space to fully implement global pharma and biotech toxicology and pharmacology drug-related projects,” a recent press release explains.